Condition
Advanced Differentiated Thyroid Gland Carcinoma
Total Trials
2
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Not Yet Recruiting1
Active Not Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT04514484Phase 1Active Not RecruitingPrimary
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
NCT06790589Phase 2Not Yet RecruitingPrimary
COACH - Comparing Two Different Methods to Suppress Thyrotropin in Patients With Advanced Thyroid Cancer
Showing all 2 trials